Vanguard Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-7,004,845
| Closed | -$126M | – | 4161 |
|
|
2020
Q2 | $126M | Buy |
7,004,845
+89,096
| +1% | +$1.24M | ﹤0.01% | 1557 |
|
|
2020
Q1 | $49.3M | Buy |
6,915,749
+170,808
| +3% | +$2.13M | ﹤0.01% | 1874 |
|
|
2019
Q4 | $161M | Buy |
6,744,941
+29,824
| +0.4% | +$823K | 0.01% | 1502 |
|
|
2019
Q3 | $180M | Buy |
6,715,117
+729,283
| +12% | +$20.5M | 0.01% | 1391 |
|
|
2019
Q2 | $162M | Buy |
5,985,834
+151,150
| +3% | +$4.74M | 0.01% | 1483 |
|
|
2019
Q1 | $202M | Buy |
5,834,684
+61,122
| +1% | +$1.76M | 0.01% | 1332 |
|
|
2018
Q4 | $113M | Buy |
5,773,562
+155,273
| +3% | +$3.19M | 0.01% | 1613 |
|
|
2018
Q3 | $150M | Sell |
5,618,289
-49,065
| -0.9% | -$1.6M | 0.01% | 1582 |
|
|
2018
Q2 | $214M | Buy |
5,667,354
+208,086
| +4% | +$7.96M | 0.01% | 1301 |
|
|
2018
Q1 | $178M | Buy |
5,459,268
+71,078
| +1% | +$3.12M | 0.01% | 1358 |
|
|
2017
Q4 | $262M | Buy |
5,388,190
+145,874
| +3% | +$7.38M | 0.01% | 1117 |
|
|
2017
Q3 | $283M | Buy |
5,242,316
+637,409
| +14% | +$37.4M | 0.01% | 1037 |
|
|
2017
Q2 | $259M | Sell |
4,604,907
-9,907
| -0.2% | -$397K | 0.01% | 1061 |
|
|
2017
Q1 | $181M | Buy |
4,614,814
+192,420
| +4% | +$6.13M | 0.01% | 1283 |
|
|
2016
Q4 | $99.2M | Buy |
4,422,394
+689,808
| +18% | +$13.5M | 0.01% | 1616 |
|
|
2016
Q3 | $84.8M | Buy |
3,732,586
+98,847
| +3% | +$2.32M | 0.01% | 1671 |
|
|
2016
Q2 | $85.8M | Buy |
3,633,739
+142,286
| +4% | +$3.51M | 0.01% | 1613 |
|
|
2016
Q1 | $71.2M | Buy |
3,491,453
+134,589
| +4% | +$4.27M | ﹤0.01% | 1691 |
|
|
2015
Q4 | $173M | Buy |
3,356,864
+290,895
| +9% | +$14.1M | 0.01% | 1104 |
|
|
2015
Q3 | $131M | Buy |
3,065,969
+88,967
| +3% | +$4.29M | 0.01% | 1254 |
|
|
2015
Q2 | $136M | Buy |
2,977,002
+543,731
| +22% | +$21.9M | 0.01% | 1330 |
|
|
2015
Q1 | $92.4M | Buy |
2,433,271
+312,804
| +15% | +$10.7M | 0.01% | 1554 |
|
|
2014
Q4 | $60.1M | Buy |
2,120,467
+457,697
| +28% | +$12.7M | ﹤0.01% | 1735 |
|
|
2014
Q3 | $42M | Buy |
1,662,770
+321,191
| +24% | +$8.46M | ﹤0.01% | 1890 |
|
|
2014
Q2 | $39.1M | Buy |
1,341,579
+73,560
| +6% | +$1.78M | ﹤0.01% | 1950 |
|
|
2014
Q1 | $32.8M | Buy |
1,268,019
+288,993
| +30% | +$7.71M | ﹤0.01% | 2019 |
|
|
2013
Q4 | $25.2M | Buy |
979,026
+525,048
| +116% | +$12.8M | ﹤0.01% | 2084 |
|
|
2013
Q3 | $12.1M | Buy |
453,978
+439,607
| +3,059% | +$10.5M | ﹤0.01% | 2306 |
|
|
2013
Q2 | $353K | Buy |
+14,371
| New | +$286K | ﹤0.01% | 3553 |
|
Vanguard Group's PTLA Position: Q3 2020 in Review
Vanguard Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 7,004,845 shares — an estimated $126M sold.
Vanguard Group first reported a position in PTLA in Q2 2013 and held it in 29 quarters. The position peaked at $283M in Q3 2017. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Vanguard Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Vanguard Group sold 7,004,845 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $126M.
- Vanguard Group first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- Vanguard Group's Portola Pharmaceuticals, Inc. position peaked at $283M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Vanguard Group's 13F filing for Q3 2020, filed 16 Nov 2020.